Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.130
+0.194 (20.69%)
At close: Aug 13, 2025, 4:00 PM
1.130
0.00 (0.00%)
Pre-market: Aug 14, 2025, 9:08 AM EDT
Fate Therapeutics Revenue
Fate Therapeutics had revenue of $1.91M in the quarter ending June 30, 2025, a decrease of -71.84%. This brings the company's revenue in the last twelve months to $8.47M, down -31.23% year-over-year. In the year 2024, Fate Therapeutics had annual revenue of $13.63M, down -78.55%.
Revenue (ttm)
$8.47M
Revenue Growth
-31.23%
P/S Ratio
15.78
Revenue / Employee
$46,796
Employees
181
Market Cap
130.32M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 13.63M | -49.90M | -78.55% |
Dec 31, 2023 | 63.53M | -32.77M | -34.03% |
Dec 31, 2022 | 96.30M | 40.45M | 72.44% |
Dec 31, 2021 | 55.85M | 24.41M | 77.66% |
Dec 31, 2020 | 31.43M | 20.75M | 194.33% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
FATE News
- 1 day ago - Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 8 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - GlobeNewsWire
- 2 months ago - Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - GlobeNewsWire
- 2 months ago - Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - GlobeNewsWire
- 3 months ago - Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 3 months ago - Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector - Seeking Alpha
- 3 months ago - Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting - GlobeNewsWire